November 15-16
Cosponsoring Publications: Antiviral Weekly, Cytokine, Frontiers in Bioscience, Immunotherapy
As key mediators of leukocyte trafficking, chemokines and their receptors hold great promise as therapeutic targets in a wide variety of disease conditions ranging from infectious diseases and inflammation to cancer. This conference will explore the newest developments in our understanding of chemokines and receptors, as well as the potential for therapeutic intervention of these chemoattractant proteins in various pathological conditions.
Scientific Advisors
Dr. Marco Baggiolini, University of Bern (Switzerland)
Dr. Joan W. Berman, Albert Einstein College of Medicine
Dr. Robert W. Doms, University of Pennsylvania
Dr. Joseph Hesselgesser, Berlex BioSciences
Dr. Thomas J. Schall, Chemocentryx, Inc.
Chairpersons
Dr. Joan W. Berman, Albert Einstein College of Medicine
Dr. Kenneth G. Carson, LeukoSite, Inc.
Dr. Joseph Hesselgesser, Berlex BioSciences
Dr. Thomas J. Schall, Chemocentryx, Inc.
Speakers
Dr. Karen Auditore-Hargreaves, NeoRx Corporation
Dr. Joan W. Berman, Albert Einstein College of Medicine
Dr. Arya Biragyn, National Cancer Institute/NIH
Dr. James Campbell, Palo Alto Institute for Research and Education
Dr. Kenneth G. Carson, LeukoSite, Inc.
Dr. Dimiter S. Dimitrov, National Cancer Institute/NIH
Dr. Jan E. Ehlert, University of Michigan Medical School
Dr. Wayne W. Hancock, LeukoSite, Inc.
Dr. Joseph Hesselgesser, Berlex BioSciences
Dr. Shalom Z. Hirschman, Advanced Viral Research Corporation
Dr. William Karpus, Northwestern University Medical School
Ms. Michelle Lohner, Abgenix, Inc.
Dr. Robin Offord, University of Geneva and Gryphon Sciences
Dr. Christine A. Power, Serono Pharmaceutical Research (Switzerland)
Dr. Richard M. Ransohoff, The Cleveland Clinic Foundation
Dr. Eric Rhodes, Sangamo BioSciences, Inc.
Dr. Thomas J. Schall, Chemocentryx , Inc.
Dr. Giovanna Tosato, Center for Biologics Evaluation and Research/FDA
Dr. Alexandra Trkola, Rockefeller University
Dr. Richard Wyatt, Dana-Farber Cancer Institute
The Science and Study: Chemokine and Receptor Biology in the Immune and Non-Immune System
Chemokines at the Dawn of the 21st Century: Aliens and Archetypes
The ELR-CXC-Chemokine Platelet Basic Protein (PBP) and Neutrophil Activation
Role of Gia2 in the Regulation of BCA-1-Induced B Cells Activation
CCR4 Knockout Mouse Models of Lung Inflammation
Expression of Chemokines and Receptors in Disease
Mechanisms of Leukocyte Trafficking Across the Blood Brain Barrier
Multiple Sclerosis
Expression Patterns in Autoimmune Encephalomyelitis Pathogenesis
Inhibition of Angiogenesis induced by IP-10/CRG-2
Allograft Rejection
New Therapeutic Applications
Chemokine Fused to Self Tumor Antigen Elicits Effective Antitumor Immunity
Pan-Chemokine Inhibitor for the Treatment of Asthma
ABX-IL8: A Fully Human Antibody for Treatment of Psoriasis
CCR1 Receptor Antagonist
Discovery and Characterization of Chemokine Receptor Antagonists
Engineering Chemokine Analogues as Anti-HIV Agents
HIV
HIV-1 Envelope Glycoproteins and Chemokine Receptors
Interactions of Chemokine Receptors with CD4 and Their Role for HIV Entry
Multiple Effects RANTES on Virus Replication
Effects of Reticulose on the Expression of CCR5
Repression of CCR5 Gene with Engineered Transcription Factors
Tuesday, November 16
3:45 Effects of the Peptide Nucleic Acid Immunomodulator, Reticulose, on the Expression of CCR5 Chemokine Receptor and It's Coordinate Chemokines
Dr. Shalom Z. Hirschman, President and CEO, Advanced Viral Research Corporation
This presentation will deal with the effects of a new "switch-type" peptide nucleic acid immunomodulator on the synthesis of chemokines in various cell systems. The address will focus on the opposite effects of the immunomodulator on the synthesis of chemokines that are important in the cytocidal action of the immune system and the CCR5 chemokine receptor. Details of the activity of the immunomodulator in down-regulating the CCR5 chemokine receptor, and modulating the coordinate chemokines involved, will be discussed.
healthtech.com |
